非小细胞肺癌 - 标靶治疗 - KOL的见解

本报告根据来自北美和欧洲的 12 位 KOL（关键意见领袖）的观点，对非小细胞肺癌 (NSCLC) 靶向治疗的发展前景进行了深入分析。主要发现包括多项3 期试验重新定义了Tagrisso 在EGFR 突变NSCLC 中的使用，Rybrevant 的使用范围扩大到利基人群之外，儘管其毒性特征较差，以及Enhertu 在HER2 突变NSCLC 中的使用有限但不断增加。

本报告研究和分析了 NSCLC 市场，强调了未满足的需求和新兴市场趋势，并全面评估了当前和未来的治疗途径。

报告涵盖的主要品牌

企业

AbbVie，Amgen，Novartis，Lilly，Roche，AstraZeneca，Pfizer，Merck & Co.，Bristol Myers Squibb，Daiichi Sankyo，Takeda，Boehringer Ingelheim，Genmab，Merck Group，Blueprint，Merus，Johnson & Johnson，Hutchmed，Rigel Pharmaceuticals，Taiho Pharmaceutical，Xcovery，Cullinan Therapeutics，Dizal Pharmaceutical

目录

摘要整理

现在与未来的治疗流程

调查目的

EGFR，HER2抑制剂

• 已批准医药品
  • Tagrisso(osimertinib，AstraZeneca)
  • Rybrevant(amivantamab-vmjw，Genmab/Johnson & Johnson)，Lazcluze/Leclaza(lazertinib，Johnson & Johnson)
• 开发平台药物品
  • Zipalertinib(Cullinan Therapeutics/Taiho Pharmaceutical)，Sunvozertinib(Dizal Pharmaceutical)，Zongertinib(Boehringer Ingelheim)，Zenocutuzumab(Merus)

抗体药物复合体

• 已批准医药品
  • Enhertu(trastuzumab deruxtecan，Daiichi Sankyo/AstraZeneca)
• 开发平台药物品
  • datopotamabuderukusutekan(Daiichi Sankyo/AstraZeneca)，Sacituzumab tirumotecan(Merck & Co.)，Patritumab deruxtecan(Daiichi Sankyo/Merck & Co.)，Telisotuzumab vedotin(AbbVie)

ALK抑制剂

• 已批准医药品
  • Alecensa(alectinib，Roche)，Alunbrig(brigatinib，Takeda)，Lorbrena/Lorviqua(lorlatinib，Pfizer)，Zykadia(ceritinib，Novartis)
• 开发平台药物品
  • Ensartinib(Xcovery)

KRAS抑制剂

• 已批准医药品
  • Krazati(adagrasib，Bristol Myers Squibb)，Lumakras/Lumykras(sotorasib，Amgen)
• 开发平台药物品
  • Olomorasib(Lilly)，MK-1084(默克)，jibarashibu(Roche)

MET抑制剂

• 已批准医药品
  • Tabrecta(capmatinib，Novartis)，Tepmetko((tepotinib，Merck Group)
• 开发平台药物品
  • Savolitinib(AstraZeneca/HUTCHMED)

RET抑制剂

• 已批准医药品
  • Gavreto(pralsetinib，Rigel Pharmaceuticals/Blueprint Medicines)，Retevmo/Retsevmo(selpercatinib，Lilly)

ROS抑制剂

• 已批准医药品
  • Augtyro(repotrectinib，Bristol Myers Squibb)

BRAF抑制剂

• 已批准医药品
  • Braftovi(encorafenib，Pfizer)，Mektovi(binimetinib，Pfizer)，Tafinlar(dabrafenib，Novartis)，Mekinist(trametinib，Novartis)

其他的作用机制

• 已批准医药品
  • Xalkori(crizotinib，Pfizer)

未来的治疗趋势

• 重要的见解的摘要

附录

KOL的快报

This report provides an in-depth analysis of the evolving landscape of targeted therapies for non-small cell lung cancer (NSCLC), based on insights from 12 key opinion leaders (KOLs) from North America and Europe. Key findings include the redefinition of Tagrisso's use in EGFR-mutated NSCLC through multiple Phase III studies, the expansion of Rybrevant's application beyond niche populations despite its challenging toxicity profile, and the limited but growing uptake of Enhertu in HER2 mutant NSCLC. The report offers a comprehensive review of current and future treatment pathways, addressing unmet needs and emerging trends in the NSCLC market.

Key brands covered in this report:

Key questions answered:

• How is the use of Tagrisso expected to evolve in the treatment of EGFRm NSCLC?
• What are the potential therapies for second-line treatment in patients resistant to third-generation EGFR-TKIs?
• How will Rybrevant's use change with new data and regulatory approvals?
• What impact will the approval of Enhertu for HER2-mutant NSCLC have on its uptake?
• Can pipeline HER2-targeting therapies like zongertinib offer competitive advantages over existing treatments?
• How will new data from studies like CROWN and ALINA affect treatment practices for ALK-positive NSCLC?
• What are the prospects for new targeted therapies for KRAS, MET, RET, ROS1, and BRAF mutations in NSCLC?
• How confident are KOLs in the impact of ADCs currently in development on the treatment paradigm?

Companies:

AbbVie, Amgen, Novartis, Lilly, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Genmab, Merck Group, Blueprint, Merus, Johnson & Johnson, Hutchmed, Rigel Pharmaceuticals, Taiho Pharmaceutical, Xcovery, Cullinan Therapeutics, Dizal Pharmaceutical.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

EGFR and HER2 inhibitors

• Approved drugs
  • Tagrisso (osimertinib; AstraZeneca)
  • Rybrevant (amivantamab-vmjw; Genmab/Johnson & Johnson) and Lazcluze/Leclaza (lazertinib; Johnson & Johnson)
• Pipeline drugs
  • Zipalertinib (Cullinan Therapeutics/Taiho Pharmaceutical); Sunvozertinib (Dizal Pharmaceutical); Zongertinib (Boehringer Ingelheim); Zenocutuzumab (Merus)

Antibody-drug conjugates

• Approved drugs
  • Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca)
• Pipeline drugs
  • Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca); Sacituzumab tirumotecan (Merck & Co.); Patritumab deruxtecan (Daiichi Sankyo/Merck & Co.); Telisotuzumab vedotin (AbbVie)

ALK inhibitors

• Approved drugs
  • Alecensa (alectinib; Roche); Alunbrig (brigatinib; Takeda); Lorbrena/Lorviqua (lorlatinib; Pfizer); Zykadia (ceritinib; Novartis)
• Pipeline drugs
  • Ensartinib (Xcovery)

KRAS inhibitors

• Approved drugs
  • Krazati (adagrasib; Bristol Myers Squibb) and Lumakras/Lumykras (sotorasib; Amgen)
• Pipeline drugs
  • Olomorasib (Lilly); MK-1084 (Merck & Co.); Divarasib (Roche)

MET inhibitors

• Approved drugs
  • Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group)
• Pipeline drugs
  • Savolitinib (AstraZeneca/HUTCHMED)

RET inhibitors

• Approved drugs
  • Gavreto (pralsetinib; Rigel Pharmaceuticals/Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly)

ROS inhibitors

• Approved drugs
  • Augtyro (repotrectinib; Bristol Myers Squibb)

BRAF inhibitors

• Approved drugs
  • Braftovi (encorafenib; Pfizer) and Mektovi (binimetinib; Pfizer); Tafinlar (dabrafenib; Novartis) and Mekinist (trametinib; Novartis)

Other mechanisms of action

• Approved drugs
  • Xalkori (crizotinib; Pfizer)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins